These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 38489062)

  • 21. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 22. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
    Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
    Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
    Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
    Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adverse events in biologics for severe asthma].
    Dargentolle G; Georges M; Beltramo G; Poisson C; Bonniaud P
    Rev Mal Respir; 2024 May; 41(5):372-381. PubMed ID: 38653607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
    Akenroye AT; Heyward J; Keet C; Alexander GC
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
    Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
    Pera V; Brusselle GG; Riemann S; Kors JA; Van Mulligen EM; Parry R; de Wilde M; Rijnbeek PR; Verhamme KMC
    Front Pharmacol; 2023; 14():1276340. PubMed ID: 38035014
    [No Abstract]   [Full Text] [Related]  

  • 37. A drug safety review of treating eosinophilic asthma with monoclonal antibodies.
    Mitchell P; Leigh R
    Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389
    [No Abstract]   [Full Text] [Related]  

  • 38. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase
    Dernoncourt A; Liabeuf S; Bennis Y; Masmoudi K; Bodeau S; Laville S; Hurtel-Lemaire AS; Gras-Champel V; Batteux B
    BioDrugs; 2023 Jan; 37(1):73-87. PubMed ID: 36401769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.